OliX Pharmaceuticals to Participate in BIO-Europe Spring®

SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company’s management will participate in one-on-one partnering meetings at BIO-Europe Spring. The event is being held digitally from March 28-31, 2022.

Dr. Sun Woo Hong, Head of External Collaboration, and Dr. June Park, Principal Scientist, will meet industry experts to discuss platform-based early discovery collaborations as well as global licensing options for pipeline programs, including OLX101A for hypertrophic scars (Phase 2), OLX703A for hepatitis B virus, and OLX702A for nonalcoholic steatohepatitis.

This year, BIO-Europe Spring, Europe’s largest springtime biopharma industry gathering, will serve the global biotechnology industry, including more than 1000 companies from 45 countries. To schedule a virtual meeting, please visit the BIO-Europe Spring^® platform at https://informaconnect.com/bioeurope-spring/partnering/.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng